Back to Journals » OncoTargets and Therapy » Volume 9

The interleukin-18 gene promoter -607 A/C polymorphism contributes to non-small-cell lung cancer risk in a Chinese population

Authors Jia Y, Zang A, Jiao S, Chen S, Yan F

Received 31 October 2015

Accepted for publication 2 February 2016

Published 21 March 2016 Volume 2016:9 Pages 1715—1719


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Min Li

Youchao Jia,1,2 Aimin Zang,2 Shunchang Jiao,1 Sumei Chen,1 Fu Yan1

1Department of Medical Oncology, General Hospital of Chinese PLA, Beijing, 2Department of Oncology, Affiliated Hospital of Hebei University, Hebei, People’s Republic of China

Abstract: The purpose of the present study was to determine the relationship between interleukin-18 (IL-18) -607 A/C polymorphism and the risk of non-small-cell lung cancer (NSCLC) and its impact on the serum IL-18 level. The genotyping of IL-18 -607 A/C polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The results showed that the AA/AC genotype distribution in NSCLC patients was significantly higher than that of healthy controls (P=0.02). However, no significant differences were found between the two subgroups when stratified by clinical characteristics. Furthermore, serum IL-18 levels were found to be significantly higher in the NSCLC patients than in the controls (P=0.01) as detected by enzyme-linked immunosorbent assay analysis. There was no correlation between serum IL-18 levels and different genotypes. In conclusion, these findings suggest that IL-18 -607 A/C polymorphism increases the risk of NSCLC in the Chinese population, and this polymorphism could not functionally affect the IL-18 levels.

Keywords: IL-18, polymorphism, NSCLC

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]